⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27879534 | 0.83 | ADRB2 (0.39) | — | |
| SCHEMBL27472038 | 0.80 | — | — | |
| SCHEMBL28213282 | 0.78 | — | — | |
| SCHEMBL27335446 | 0.75 | — | — | |
| SCHEMBL691901 | 0.72 | — | — | |
| SCHEMBL6471512 | 0.72 | — | — | |
| SCHEMBL9509371 | 0.72 | — | — | |
| SCHEMBL1149434 | 0.72 | — | — | |
| SCHEMBL128926 | 0.69 | — | — | |
| SCHEMBL6547844 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102575109-B | Azo compounds, ink compositions, and colored bodies | NIPPON KAYAKU KK | 2014-07-09 | — | — | CN | claimed |
| CN-102575109-A | Azo compounds, ink compositions, and colored bodies | NIPPON KAYAKU KK | 2012-07-11 | — | — | CN | claimed |
| CN-108271387-B | RNAi therapy of hepatitis B virus infection | 箭头药业股份有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-115957337-A | RNAi therapy for hepatitis B virus infection | 箭头药业股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115678542-A | Quaternary nanostructure based on bright silver | 纳米系统公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-113840895-B | Quaternary nanostructure based on bright silver | 纳米系统公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-113493789-A | Compositions and methods for inhibiting gene expression of factor XII | 箭头药业股份有限公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-113444725-A | Compositions and methods for inhibiting alpha-1 antitrypsin gene expression | 箭头药业股份有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-108064313-B | Compositions and methods for inhibiting gene expression of factor XII | 箭头药业股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-106535917-B | Compositions and methods for inhibiting alpha-1 antitrypsin gene expression | 箭头药业股份有限公司 | 2021-07-06 | — | — | CN | disclosed |
| CN-102491969-B | Heteroaromatic quinoline compounds and the purposes as PDE10 inhibitor thereof | PFIZER PRODUCTS INC. (US) | 2015-08-19 | — | — | CN | disclosed |
| CN-101500548-A | Polyconjugates for in vivo delivery of polynucleotides | HOFFMANN LA ROCHE (CH) | 2009-08-05 | — | — | CN | disclosed |
| US-20090176829-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2009-07-09 | — | — | US | disclosed |
| US-7429665-B2 | Heteroaromatic quinoline compounds | PFIZER INC (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080214607-A1 | HETEROAROMATIC QUINOLINE COMPOUNDS | PFIZER INC | 2008-09-04 | — | — | US | disclosed |
| EP-1841757-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Pfizer Products Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070155779-A1 | BICYCLIC HETEROARYL COMPOUNDS AS PDE10 INHIBITORS | PFIZER INC | 2007-07-05 | — | — | US | disclosed |
| US-20060154931-A1 | Heteroaromatic quinoline compounds | PFIZER INC | 2006-07-13 | — | — | US | disclosed |
| WO-2006072828-A2 | HETEROAROMATIC QUINOLINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| CN-1334801-A | Biphenyl and biphenyl-analogous compounds as integrin antagonists | BAYER AG (DE) | 2002-02-06 | — | — | CN | disclosed |